# US 12,213,986 B1 · Compositions and methods for treating epilepsy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,213,986 B1 - Document ID: US12213986B1 - Status: Granted - Kind: B1 - Application number: 18/417,252 - Filed: 2024-01-19 - Published: 2025-01-30 - Granted: 2025-02-04 - Earliest claimed: 2023-07-24 - Applicants: Poviva Corp - Inventors: John Docherty; Christopher Andrew Bunka - Web page: https://patentgrep.com/patent/US12213986B1 ## CPC - A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol} - A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals} - A61K 9/2009: {Inorganic compounds} - A61K 9/2013: {Organic compounds, e.g. phospholipids, fats} - A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin} - A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)} - A61K 9/4858: {Organic compounds} - A61K 9/4866: {Organic macromolecular compounds} - A61K 31/05: Phenols {(cannabinoids A61K31/658)} - A61P 15/10: for impotence - A61P 25/08: Antiepileptics; Anticonvulsants - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy. ## Claims ### Claim 1 A composition consisting of: a) from about 35 mg to about 150 mg of CBD oil extract containing at least about 98% by weight of cannabidiol; b) from about 70 mg to about 300 mg of olive oil; c) from about 3 mg to about 13 mg of deoxycholic acid; d) from about 135 mg to about 560 mg of mannitol, colloidal silicon dioxide, or a mixture thereof. ### Claim 2 (depends on 1) The composition according to claim 1, consisting of from about 35 mg to about 120 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 3 (depends on 1) The composition according to claim 1, consisting of from about 35 mg to about 95 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 4 (depends on 1) The composition according to claim 1, consisting of from about 35 mg to about 75 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 5 (depends on 1) The composition according to claim 1, consisting of from about 75 mg to about 150 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 6 (depends on 1) The composition according to claim 1, consisting of from about 75 mg to about 120 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 7 (depends on 1) The composition according to claim 1, consisting of from about 75 mg to about 95 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 8 (depends on 1) The composition according to claim 1, consisting of from about 95 mg to about 120 mg of CBD oil extract containing at least about 98% by weight of cannabidiol. ### Claim 9 (depends on 1) The composition according to claim 1, consisting of from about 70 mg to about 250 mg of olive oil. ### Claim 10 (depends on 1) The composition according to claim 1, consisting of from about 70 mg to about 190 mg of olive oil. ### Claim 11 (depends on 1) The composition according to claim 1, consisting of from about 150 mg to about 300 mg of olive oil. ### Claim 12 (depends on 1) The composition according to claim 1, consisting of from about 90 mg to about 300 mg of olive oil. ### Claim 13 (depends on 1) The composition according to claim 1, consisting of from about 70 mg to about 240 mg by weight of olive oil. ### Claim 14 (depends on 1) The composition according to claim 1, consisting of from about 70 mg to about 190 mg by weight of olive oil. ### Claim 15 (depends on 1) The composition according to claim 1, consisting of from about 150 mg to about 300 mg by weight of olive oil. ### Claim 16 (depends on 1) The composition according to claim 1, consisting of from about 190 mg to about 300 mg by weight of olive oil. ### Claim 17 (depends on 1) The composition according to claim 1, consisting of from about 135 mg to about 440 mg of a carrier selected from the group consisting of from mannitol, colloidal silicon dioxide, and a mixture thereof. ### Claim 18 (depends on 1) The composition according to claim 1, consisting of from about 135 mg to about 360 mg of a carrier selected from the group consisting of from mannitol, colloidal silicon dioxide, and a mixture thereof. ### Claim 19 (depends on 1) The composition according to claim 1, consisting of from about 135 mg to about 280 mg of a carrier selected from the group consisting of from mannitol, colloidal silicon dioxide, and a mixture thereof. ### Claim 20 (depends on 1) The composition according to claim 1, consisting of from about 280 mg to about 560 mg of a carrier selected from the group consisting of from mannitol, colloidal silicon dioxide, and a mixture thereof. ### Claim 21 (depends on 1) The composition according to claim 1, consisting of about 67 mg of mannitol and about 68 mg of colloidal silicon dioxide. ### Claim 22 (depends on 1) The composition according to claim 1, consisting of about 139 mg of mannitol and about 141 mg of colloidal silicon dioxide. ### Claim 23 (depends on 1) The composition according to claim 1, consisting of about 139 mg of mannitol and about 141 mg of colloidal silicon dioxide. ### Claim 24 (depends on 1) The composition according to claim 1, consisting of about 143 mg of mannitol and about 144 mg of colloidal silicon dioxide.